ClinicalTrials.gg
CompletedNCT05176626LEAPUpdated Nov 5, 2026

Long-term Effectiveness of the Antiobesity Medication Phentermine

A Phase 4 interventional study of Online Lifestyle Behavioral Therapy and Phentermine Hydrochloride 8 MG in Obesity, Obesity; Drug and Lifestyle, Healthy, sponsored by Wake Forest University Health Sciences. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
870
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing phentermine in Obesity — 3 open to participants now, 4 under way, none of them phase 3. Phentermine · Obesity.

Enrollment
3rd of 26
870 · median 134
Started
2022
with 1 other
Phase 4
13 of 26
2 open now
Registered
21st of 26
by date
Lead sponsor
3 of 26
Wake Forest University Health Sciences

Among the 26 studies testing phentermine in Obesity, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 13 in phase 4, and was the 21st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 26 studies testing phentermine in Obesity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About phentermine

Phentermine: first FDA approval 1959 (IONAMIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing phentermine in Obesity, or all of them as a file.
02

Study summary

The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.

Read the detailed description

The Long-term Effectiveness of the Anti-obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized trial, will be conducted at 5 clinical sites across the United States. All participants will be provided with an evidence-based online lifestyle intervention, and participants receiving 24 mg/day of phentermine vs. a placebo for up to 24 months will be compared in an intent-to-treat fashion. The co-primary outcomes of percent weight loss and change in systolic blood pressure at 24 months will be examined. Also, between group changes in drivers of energy balance, including resting metabolic rate, caloric intake, physical activity and dietary composition will be compared. To explore the effects of weight loss on cardiometabolic health, changes in heart rate, hemoglobin A1c, lipids, waist circumference, atherosclerotic cardiovascular disease (ASCVD) risk score, and novel ECG markers of cardiac strain will be compared. Overall adverse event and serious adverse event rate, including rates of incident cardiovascular disease or death, will be measured.

03

Conditions studied

  • Obesity
  • Obesity; Drug
  • Lifestyle, Healthy

Keywords

  • weight-loss
  • lifestyle intervention
  • phentermine
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 30-44.9 kg/m2 or BMI 27-29.9 with weight related comorbidity (including hypertension, prediabetes, type 2 diabetes mellitus, dyslipidemia, nonalcoholic fatty liver disease, treated obstructive sleep apnea, osteoarthritis, low back pain, gastroesophageal reflux disease)
  • English-speaking
  • Has a smartphone or other device with regular internet access
  • Interested in and willing to lose weight as a result of treatment
  • Able to take oral medication and willing to adhere to the clinical visit schedule for the trial and lifestyle based treatment regimen throughout the study duration, as recommended by the study clinician
  • For females of : use of effective for at least 1 month prior to randomization and agreement to use such a method during study participation and for an additional 8 weeks after the end of study drug administration
  • Provision of electronically-signed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery, cerebrovascular or peripheral arterial disease including myocardial infarction, unstable angina, revascularization, stroke/, carotid intervention, claudication
  • Poorly-controlled blood pressure (>149/94) or elevated heart rate (>110 bpm)
  • History of cardiac arrhythmia
  • Active / currently-treated hyperthyroidism
  • History of glaucoma or been told by an ophthalmologist that you are at high risk for glaucoma
  • Heavy alcohol use within the last 6 months (men: more than 4 drinks on any day or more than 14 drinks per week; women: more than 3 drinks on any day or more than 7 drinks per week)
  • History of substance use disorder or active use of illicit substances within the last 12 months. Tetrahydrocannabinol (THC)-containing products will not be considered an illicit substance.
  • Use of a drug in the monoamine oxidase inhibitor class, currently or within the last 14 days
  • Currently pregnant or lactating/breastfeeding; intention to get pregnant in next 24 months; seeking or in active treatment for infertility
  • End-stage renal disease on dialysis or CKD class IV or higher ( \<30)
  • History of valvular heart disease
  • Congestive heart failure (any history or current)
  • Cirrhosis or symptoms of liver failure in the last 2 years
  • Severe pulmonary disease requiring supplemental oxygen
  • Quit using nicotine-containing products less than 6 months prior to baseline visit or intention to quit use in the next 2 years
  • Use of oral more than 5 days/month in the last 3 months
  • Elevated depressive symptoms
  • Uncontrolled anxiety symptoms
  • Hospitalization for mental illness in the last 24 months
  • Diagnosis of dementia or serious mental illness (e.g., schizophrenia, bipolar disorder, severe depression)
  • Binge Eating Disorder, Bulimia or Anorexia Nervosa diagnosis or treatment within the last 2 years
  • Prior procedure for weight control (including bariatric surgery, devices)
  • Use of phentermine, phentermine-containing medication, or anti-obesity medication with similar mechanism of action to phentermine (e.g., phendimetrazine or diethylpropion) in the previous 24 months
  • Use of any non-phentermine-containing medications prescribed for weight loss in previous 12 months
  • Unstable dose of weight-loss-promoting medications within the last 12 months. Weight-loss-promoting medications are medication prescribed for another condition, but are known to have weight loss effects. Examples would include use of a GLP1 agonist or SGLT2 inhibitor in patients with diabetes; use of topiramate among patients with migraine headaches.
  • Use of any stimulant medications in previous 12 months
  • Known allergy or intolerance to phentermine or phentermine-containing medication
  • Documented or self-reported weight change (gain or loss) of more than 5% of current body weight in the past 3 months
  • History of cancer other than non-melanoma skin cancer in the past 5 years
  • History of organ transplantation
  • Plan to move outside the area in the next two years
  • Unable to make changes to diet (e.g., severe food allergies or intolerances; medically necessary aspects of diet incompatible with intervention)
  • Already participating in another research study that includes lifestyle changes and/or study medication or has participated in such a study within the last 12 months
  • Total body weight that exceeds 400 lbs., precluding use of the digital scale in the lifestyle intervention
  • Upper arm circumference that exceeds 50 cm, precluding use of the OMRON HEM 907 XL to measure blood pressure
  • Other concern or medical comorbidity that, per discretion of study clinician, would render the participant unfit or unable to safely take part in the 24-month intervention
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
870 participants (actual)

Study arms

  • Experimental
    Phentermine

    Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.

    Behavioral: Online Lifestyle Behavioral Therapy · Drug: Phentermine Hydrochloride 8 MG

  • Placebo comparator
    Placebo

    Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.

    Behavioral: Online Lifestyle Behavioral Therapy

Interventions

  • BehavioralOnline Lifestyle Behavioral Therapy

    Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.

  • DrugPhentermineStudies of PhenterminePhentermine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.

    Also known as: Lomaira

06

What researchers measure

Primary outcomes

  1. Change in body weight (%)

    The primary outcome for efficacy will be percent weight loss at 24 months of follow-up, relative to body weight (kg) at randomization.

    Time frame: Baseline to month 24

  2. Change in Systolic Blood Pressure (mmHg)

    The primary outcome to address phentermine's impact on a key cardiovascular disease risk factor, blood pressure, will be assessed at 24 months. Staff will measure BP using a standardized protocol with automated BP measurement devices (Omron HEM907XL) and following standard clinical practice guidelines for blood pressure measurement.

    Time frame: Baseline to month 24

Secondary outcomes

  1. Change in resting energy expenditure (REE) / resting metabolic rate (RMR)

    RMR will be measured via indirect calorimetry using the KORR ReeVue (KORR Medical Technologies, Salt Lake City, UT).

    Time frame: Baseline to month 6; Baseline to month 24

  2. Change in cardiac autonomic function

    Change in cardiac autonomic function will be measured using heart rate variability with electrocardiogram (ECG). Heart rate variability (HRV) and resting heart rate (RHR) are noninvasive measures of cardiac autonomic function.

    Time frame: Baseline to month 3; Baseline to month 6; Baseline to month 12; Baseline to month 24

  3. Dependence on study drug (phentermine)

    Dependence on study drug will be assessed using the Severity of Dependence Scale (SDS), a brief 5-item validated measure of psychological dependence that has been used for both illegal drugs of abuse and prescription drugs with concern for addiction potential. The score ranges from 0-15 with a higher score denoting a stronger dependence on the study drug.

    Time frame: Month 24

  4. Change in Systolic Blood Pressure (mmHg)

    To address phentermine's impact on blood pressure over the course of the study, change in systolic blood pressure will be assessed at 6 months using a standardized measurement protocol with automated BP devices and following standard clinical practice guidelines for blood pressure measurement.

    Time frame: Baseline to month 6; Baseline to month 12; Baseline to month 18

Other outcomes

  1. Incident cardiovascular disease or death

    To address the impact of phentermine on cardiovascular disease and total mortality, participant diagnoses, hospitalizations, treatment, and deaths will be tracked via a combination of self-report and tracking within the electronic medical record.

    Time frame: Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24

  2. Change in body weight (%)

    To assess the efficacy of phentermine at intervals throughout the study, percent weight loss at 6 and 12 months of follow-up relative to body weight (kg) at randomization will be measured.

    Time frame: Baseline to month 6; Baseline to month 12

  3. Change in self-reported physical activity levels

    The International Physical Activity (IPAQ) short form is a 7-item index that asks respondents the number of days per week and the amount of time per day spent in vigorous- and moderate-intensity activities and walking, during the seven days prior to the visit. Different levels of physical activity are assigned metabolic equivalent (MET) scores based on the Compendium of Physical Activity and, using MET-minutes, can be converted to both continuous and categorical values

    Time frame: Baseline to month 6; Baseline to month 12; Baseline to month 24

07

Study locations

4 sites
  • Kaiser Permanente Southern California
    Los Angeles, California 90034, United States
  • HealthPartners Institute
    Saint Louis Park, Minnesota 55416, United States
  • Atrium Health Wake Forest Baptist Weight Management Center
    Winston-Salem, North Carolina 27104, United States
  • UT Center for Obesity Medicine and Metabolic Performance
    Bellaire, Texas 77401, United States
08

References and documents

Publications

  • Young CB, Rives E, Gudzune KA, Jaeger BC, Simmons CG, White BN, Hooker SA, Horn DB, Young DR, Vesely J, Velazquez A, Price C, Cook SD, Martin-Fernandez K, Inzhakova G, Pajewski NM, Ard JD, Lewis KH. The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics. Contemp Clin Trials. 2026 Feb;161:108219. doi: 10.1016/j.cct.2026.108219. Epub 2026 Jan 8. PubMed 41519431 ↗
  • Ziegenfuss JY, Sour EU, Roelofs EJ, Vesely JM, Margolis KL, Hooker SA. A randomized study comparing patient portal and email communications for trial recruitment. Clin Trials. 2025 Oct;22(5):597-606. doi: 10.1177/17407745251358259. Epub 2025 Aug 21. PubMed 40836901 ↗
  • Heeren FAN, Ruddiman KR, Simmons C, White BN, Jaeger BC, Pajewski NM, Hooker SA, Horn DB, Martin-Fernandez K, Gudzune KA, Young CB, Ard J, Lewis KH. Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial. Obesity (Silver Spring). 2026 Jan;34(1):58-64. doi: 10.1002/oby.70070. Epub 2025 Oct 27. PubMed 41145317 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2026, 51 months.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 51 months is above that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 4, 2022
StartActual
Jun 30, 2022
Primary completionActual
Sep 30, 2026was Dec 2026
CompletionActual
Sep 30, 2026was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Primary completion
Dec 31, 2026→Sep 30, 2026 (actual)
Nov 5, 2026
Study completion
Dec 31, 2026→Sep 30, 2026 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2026→Sep 30, 2026 (now actual)
    Study completion Dec 31, 2026→Sep 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05176626
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Jun 30, 2022
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 5, 2026

Study contacts

Kristina H Lewis, MD
principal investigator · Wake Forest University Health Sciences
Jamy D Ard, MD
principal investigator · Wake Forest University Health Sciences
Nicholas M Pajewski, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentermine

Start the discussion